Evidence map›Paper›PMID 30456701›Full record

ArticleLung2019

Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome.

David Bennett, Antonella Fossi, Giuseppina Chiarello, Rosa Metella Refini, Luca Luzzi, Piero Paladini, Maria Materozzi, Natale Figura, Ranuccio Nuti, Paola Rottoli

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Microorganisms · 2021
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David BennettRespiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy. david.btt@gmail.com.ORCID 0000-0001-5354-152X
Antonella FossiRespiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy.
Giuseppina ChiarelloRespiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy.
Rosa Metella RefiniRespiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy.
Luca LuzziThoracic Surgery, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Piero PaladiniThoracic Surgery, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Maria MaterozziInternal Medicine, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Natale FiguraInternal Medicine, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Ranuccio NutiInternal Medicine, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Paola RottoliRespiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy.
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori (HP) is a spiral, gram-negative, microaerophilic bacterium that colonises the human gastric mucosa and is associated with gastrointestinal and extragastrointestinal disorders. Since no data are yet available on HP infection in lung transplant patients, we evaluated the prevalence and impact of HP infection in a population of such patients.

methodsSixty-seven lung transplant patients were enrolled in the study (35 females and 32 males, age 48.4 ± 13.3 years), 54 underwent bilateral and 13 single lung transplant. Serum antibodies against HP and CagA were assayed in all subjects.

resultsThe prevalence of HP infection in lung transplant patients was similar to that in the general population (49.25% vs. 51.4%), whereas HP-positive patients showed lower CagA positivity (9% vs. 50.2%, p < 0.0001). There was a higher prevalence of HP infection in patients who underwent lung transplant because of pulmonary fibrosis (p = 0.049), and a lower prevalence in COPD patients (p = 0.011). No correlation was found between HP infection in lung transplant patients and graft outcome. No differences in primary graft dysfunction, acute rejection or bronchiolitis obliterans syndrome-free survival were found. However, more patients who required three or more post-transplant re-hospitalisations were observed among HP-positive patients.

conclusionsThe prevalence of HP infection in lung transplant patients was comparable to that of the general population and to that reported in heart and kidney transplant recipients. It did not seem to impact short-, mid- or long-term lung allograft outcome. H. pylori infection did not prove to be clinically relevant in lung transplant patients.

Indexed as

Lung TransplantationAdultFemaleHelicobacter InfectionsHelicobacter pyloriHumansItalyLung DiseasesMaleMiddle AgedPatient ReadmissionPostoperative ComplicationsPrevalenceRisk FactorsTime FactorsTreatment OutcomeEpidemiologyHelicobacter pyloriLung transplantation

Identifiers

PMID30456701
OpenAlexW2901200772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.